In this video, Dr. Sarah Telaney, a breast medical oncologist at Dana-Farber Cancer Institute, shares key takeaways from ESMO 2024, highlighting three impactful studies in breast oncology. She discusses the promising outcomes of preoperative pembrolizumab for early-stage triple-negative breast cancer, the significant efficacy of trastuzumab deruxtecan (T-DXd) in patients with metastatic HER2-positive disease and brain metastases, and the recently FDA-approved ribociclib for early-stage hormone receptor-positive breast cancer. Dr. Telaney emphasizes the exciting pace of drug development and its potential to improve patient care.

The five-day Menopause Society (formerly the North American Menopause Society) 2024 annual meeting took place Sept. 10 to 14 at the Hyatt Regency in Chicago. The agenda was jam-packed with the latest research in understanding and treating menopausal symptoms, with a special focus on artificial intelligence in the women’s health landscape.

Click the link above to find our postconference wrap-up report.